Exscientia (NASDAQ:EXAI) Price Target Raised to $21.00 at Morgan Stanley

Exscientia (NASDAQ:EXAIGet Rating) had its target price upped by Morgan Stanley from $20.00 to $21.00 in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm currently has an equal weight rating on the stock.

Separately, Zacks Investment Research lowered shares of Exscientia from a buy rating to a hold rating in a research report on Wednesday, March 9th.

Shares of NASDAQ:EXAI opened at $15.08 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.72 and a quick ratio of 12.71. Exscientia has a 12-month low of $11.10 and a 12-month high of $30.38. The stock’s fifty day moving average is $15.68.

Exscientia (NASDAQ:EXAIGet Rating) last issued its earnings results on Wednesday, March 23rd. The company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.79). The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $21.33 million. Analysts expect that Exscientia will post -0.49 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Davidson Kempner Capital Management LP bought a new position in Exscientia during the fourth quarter valued at approximately $198,000. Citigroup Inc. bought a new stake in shares of Exscientia during the 4th quarter valued at $298,000. TD Asset Management Inc. bought a new stake in shares of Exscientia during the 4th quarter valued at $402,000. Squarepoint Ops LLC purchased a new position in Exscientia during the fourth quarter valued at $712,000. Finally, Russell Investments Group Ltd. purchased a new position in Exscientia during the fourth quarter valued at $1,002,000. Institutional investors own 16.10% of the company’s stock.

About Exscientia (Get Rating)

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.

Recommended Stories

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.